● Home  

● Random  

● Nearby  



● Log in  



● Settings  



● Donate  



● About Wikipedia  

● Disclaimers  



Wikipedia





PF-4455242





● Article  
● Talk  


● Language  

● Watch  

● Edit  





PF-4455242 is a selective, short-acting (non-"inactivating") antagonist of the κ-opioid receptor.[1][2] Discovered by Pfizer in 2009, it was pursued in a phase I clinical trial for the treatment of bipolar disorder,[3] and was also investigated as a treatment for depression and substance abuse.[4] However, development was stopped in September 2010 due to toxicology findings in animals that had been exposed to the drug for three months.[3]

PF-4455242
Clinical data
Routes of
administration		Oral
ATC code
  • None
Identifiers

  • 2-Methyl-N-{[2’-(1-pyrrolidinylsulfonyl)-4-biphenylyl]methyl}-1-propanamine

CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H28N2O2S
Molar mass372.53 g·mol−1
3D model (JSmol)

  • CC(C)CNCC1=CC=C(C=C1)C2=CC=CC=C2S(=O)(=O)N3CCCC3

  • InChI=1S/C21H28N2O2S/c1-17(2)15-22-16-18-9-11-19(12-10-18)20-7-3-4-8-21(20)26(24,25)23-13-5-6-14-23/h3-4,7-12,17,22H,5-6,13-16H2,1-2H3

  • Key:OWVIKBRKPCTDEP-UHFFFAOYSA-N

See also

edit

References

edit
  1. ^ Verhoest PR, Basak AS, Parikh V, Hayward M, Kauffman GW, Paradis V, et al. (August 2011). "Design and discovery of a selective small molecule κ opioid antagonist (2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine, PF-4455242)". Journal of Medicinal Chemistry. 54 (16): 5868–5877. doi:10.1021/jm2006035. PMID 21744827.
  • ^ Melief EJ, Miyatake M, Carroll FI, Béguin C, Carlezon WA, Cohen BM, et al. (November 2011). "Duration of action of a broad range of selective κ-opioid receptor antagonists is positively correlated with c-Jun N-terminal kinase-1 activation". Molecular Pharmacology. 80 (5): 920–929. doi:10.1124/mol.111.074195. PMC 3198912. PMID 21832171.
  • ^ a b Chaki S, Kanuma K (2012). "Neuropeptide Receptors: Novel Therapeutic Targets for Depression and Anxiety Disorders". In Rankovic Z, Hargreaves R, Bingham M (eds.). Drug Discovery for Psychiatric Disorders. Royal Society of Chemistry. pp. 314–317. ISBN 978-1-84973-365-6.
  • ^ Goli V, Pryde D, Omoto K (2013). "Oral Opioids". In Allerton C, Fox D (eds.). Pain Therapeutics: Current and Future Treatment Paradigms. Royal Society of Chemistry. p. 50. ISBN 978-1-84973-645-9.
    • edit
     

    This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

  • t
  • e

    • Retrieved from "https://en.wikipedia.org/w/index.php?title=PF-4455242&oldid=1190949724"
      



    Last edited on 20 December 2023, at 20:00  





    Languages

     



    This page is not available in other languages.
      

     Wikipedia


    ●This page was last edited on 20 December 2023, at 20:00 (UTC).
    ●Content is available under CC BY-SA 4.0 unless otherwise noted.


    ●Privacy policy
    ●About Wikipedia
    ●Disclaimers
    ●Contact Wikipedia
    ●Code of Conduct
    ●Developers
    ●Statistics
    ●Cookie statement
    ●Terms of Use
    ●Desktop